MedTrace Logo

Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)

NCT00237588 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-07-06

No results posted yet for this study

Summary

To determine if angiotensin-II AT-1 receptor blockade(ARB) may improve insulin sensitivity assessed by the hyperinsulinaemic isoglycaemic glucose clamp, more than CCB therapy at a comparable dose with regards to the blood pressure-lowering effect.

Conditions

Interventions

DRUG

Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg

Sponsors & Collaborators

Principal Investigators

  • Sverre E Kjeldsen, MD, PhD · Ullevaal University Hospital

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2005-07-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00237588 on ClinicalTrials.gov